Drug intelligence / Profile preview

IXA-002

Development stage: Preclinical
Lead developer: IXALTIS
Modality: Small Molecules

Overview

**IXA-002** is a small molecule dual inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) developed by IXALTIS SAS for urological disorders. It selectively targets these enzymes to modulate monoamine neurotransmitter levels, potentially addressing symptoms in conditions like overactive bladder or lower urinary tract symptoms. Currently in preclinical development, it represents part of IXALTIS's pipeline focused on innovative urological therapeutics, with no reported clinical data or approved indications yet.[3][7]

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on IXA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IXA-002.

Explore the full profile